Does Medicare cover Wegovy for weight loss?

Medicare Part D cannot cover Wegovy when prescribed solely for weight loss — this is a statutory exclusion under MMA 2003 §1860D-2(e)(2)(A). However, the FDA approved Wegovy for cardiovascular event reduction in 2024 based on the SELECT trial. Medicare Part D plans began adding coverage for Wegovy under this CVD indication in 2024-2025 for patients with established cardiovascular disease and obesity/overweight.

Why does insurance cover Ozempic but not Wegovy?

Ozempic and Wegovy contain the same active ingredient (semaglutide) but have different FDA-approved uses: Ozempic for type 2 diabetes, Wegovy for chronic weight management. Most insurance plans cover medications based on the FDA-labeled indication. Type 2 diabetes is consistently covered; weight-management coverage varies by plan, employer, and state. Many employers exclude obesity drugs as "lifestyle" medications despite being FDA-approved.

How do I get prior authorization approved for a GLP-1?

Most prior auths require documented BMI ≥30 (or ≥27 with a comorbidity like type 2 diabetes, hypertension, hyperlipidemia, or sleep apnea), a recent A1C if diabetic, documentation of lifestyle intervention attempts, and contraindication screening. Your prescriber submits the form through the insurer's portal; turnaround is typically 24-72 hours. If denied, request the specific denial reason in writing — this informs the appeal strategy.

What can I do if my GLP-1 prescription is denied?

Three-step approach: (1) Request the written denial reason and your plan's formulary exception process. (2) Submit a tier-exception or formulary-exception appeal with prescriber-supplied medical necessity letter citing FDA labels, treatment guidelines, and your failure of other therapies. (3) If denied again, request external review (independent third-party medical review, available under ACA-regulated plans). Many denials are reversed on appeal with proper documentation.

Are there manufacturer savings programs that work with insurance?

Yes, but eligibility is restrictive. NovoCare offers commercially-insured Wegovy and Ozempic patients $0-25/month copay cards (capped annual savings). LillyCares similarly covers Zepbound and Mounjaro for commercially-insured patients. Both programs EXCLUDE Medicare, Medicaid, and uninsured patients due to federal anti-kickback rules. LillyDirect (separate from copay cards) sells Zepbound single-dose vials at $349-499/month cash-pay regardless of insurance.

Does Medicaid cover GLP-1s for weight loss?

Medicaid weight-loss coverage is state-by-state. As of 2026, approximately 13 states explicitly cover GLP-1s for chronic weight management under their Medicaid programs (typically with BMI ≥30 + comorbidity criteria). Most state Medicaids cover diabetes indications consistently. See our state-by-state pages for current coverage status in your state.

GLP-1 Insurance Coverage 2026 — Complete Reference (Commercial, Medicare, Medicaid)

The 60-second answer

GLP-1 coverage in 2026 has three tiers: commercial plans cover diabetes drugs uniformly, weight-loss drugs inconsistently (employer plan-dependent, often requires prior auth). Medicare Part D statutorily cannot cover weight-loss-only drugs (MMA 2003), but does cover Wegovy under its 2024 cardiovascular indication and most diabetes GLP-1s. Medicaid coverage of GLP-1s for weight management is state-by-state — about 13 states do as of 2026. If denied: request written denial reason, file a formulary-exception appeal with a prescriber-supplied medical necessity letter, and escalate to external review under ACA rules if needed.

1. Why GLP-1 coverage is so fragmented

GLP-1 medications occupy an unusual position in the US insurance landscape because they sit at the intersection of three regulatory regimes:

Diabetes coverage: Universally covered as a chronic disease — Ozempic, Mounjaro, Rybelsus, Trulicity included on virtually every formulary.
Obesity coverage: Treated inconsistently — many plans (and Medicare Part D) classify obesity drugs as “lifestyle” medications excluded from coverage, despite obesity being recognized as a disease by the AMA since 2013.
Cardiovascular coverage: Added in 2024 when FDA approved Wegovy for CVD event reduction based on the SELECT trial — created a coverage pathway for some otherwise-excluded patients.

The same molecule (semaglutide) sold under two brand names with two indications ends up covered under one (Ozempic for diabetes) and not the other (Wegovy for weight) by the same plan. This drives much of the patient frustration around GLP-1 access.

2. Commercial insurance: what to expect

Commercial coverage depends primarily on your employer's plan design. Three patterns dominate:

Pattern A: Full coverage with prior auth (~40% of plans)

Both diabetes and weight indications covered, but PA required. Typical criteria: BMI ≥30 or BMI ≥27 with a documented comorbidity (T2D, hypertension, dyslipidemia, OSA, CVD). Documentation of at least 3-6 months of lifestyle intervention attempts may be required.

Pattern B: Diabetes-only (~35% of plans)

Ozempic, Mounjaro, Rybelsus covered for T2D; Wegovy, Zepbound, Saxenda explicitly excluded. Common in older PBM contracts and plans that haven't updated formularies since the 2021 Wegovy launch.

Pattern C: Weight-loss covered with copay tier (~25% of plans)

Newer employer plans (often tech, finance, and large self-insured employers) increasingly cover weight indications, sometimes with a higher copay tier or annual benefit cap.

Check your specific plan: log into your insurer's member portal, search the formulary for the specific brand (not the generic name), and note the tier. Tier 3-4 typically means PA required plus higher cost share.

3. Medicare Part D rules + the CVD exception

Medicare Part D, the prescription drug benefit, is governed by the Medicare Modernization Act of 2003 (MMA). Section 1860D-2(e)(2)(A) explicitly excludes “agents when used for anorexia, weight loss, or weight gain” from Part D coverage. This is statutory — individual plans cannot override it.

Practical effect: Wegovy, Zepbound, and Saxenda are NOT covered by Part D when prescribed for weight loss alone. Diabetes-indicated GLP-1s (Ozempic, Mounjaro, Rybelsus, Trulicity) are covered when prescribed for type 2 diabetes.

The 2024 CVD exception

In March 2024, the FDA approved Wegovy for cardiovascular event reduction in adults with established cardiovascular disease and overweight or obesity, based on the SELECT trial. This created a separate (non-weight-loss) indication that Part D can cover.

Medicare Part D plans began adding Wegovy coverage under this CVD indication in mid-2024. Eligibility requires documented established CVD (prior MI, stroke, or symptomatic peripheral artery disease) plus BMI ≥27. Coverage is plan-specific — check your Part D plan's formulary annually.

The Treat and Reduce Obesity Act (TROA) has been proposed in multiple Congresses to amend the MMA exclusion. As of mid-2026, it has not passed.

4. Medicaid: state-by-state landscape

Medicaid has dual-program structure: federal floor + state discretion. Diabetes drugs are uniformly covered. Weight-management drugs are state-by-state.

States that explicitly cover GLP-1s for chronic weight management as of 2026 (typically with BMI + comorbidity criteria): California, Connecticut, Delaware, Illinois, Massachusetts, Michigan, Minnesota, New Hampshire, Pennsylvania, Rhode Island, Virginia, Washington, Wisconsin.

See our state-by-state pages for current Medicaid coverage details, prior-auth criteria, and patient eligibility per state. Coverage criteria change — we update these monthly.

5. Prior authorization checklist

Most insurers require prior authorization (PA) for GLP-1 weight indications. Have these ready before your appointment to maximize first-pass approval rate:

Current BMI (calculated from a clinic-measured height + weight)
Comorbidity documentation: A1C if diabetic, blood pressure logs if hypertensive, sleep study if OSA, lipid panel if dyslipidemic
Lifestyle intervention history: 3-6 months of documented diet/exercise attempts (clinic visits, dietitian notes, programs like Noom, Weight Watchers)
Failed prior medications: any previous weight-loss drugs tried (phentermine, orlistat, naltrexone-bupropion) with reason for discontinuation
Contraindication screening: confirmed no personal/family history of medullary thyroid carcinoma or MEN 2
Insurance card + member ID + specific plan name

Many practices have a dedicated PA coordinator. If yours doesn't, ask the medical assistant who handles PAs and confirm they have a template for the relevant GLP-1.

6. If your prescription is denied: 3-step appeal

Step 1 — Get the denial in writing: Insurers must provide the specific denial reason. Call the member services number on your card and request the written denial letter. Note the exact denial code or rationale.
Step 2 — File a formulary-exception or tier-exception appeal: Your prescriber submits a medical-necessity letter responding to the specific denial reason. This letter should cite the FDA label, relevant clinical guidelines (AACE, ADA, ASMBS), your medical history, and why preferred alternatives are inadequate.
Step 3 — External review (if denied again): Under the ACA, ACA-regulated plans must allow independent external review by a third-party medical reviewer. Request this in writing within the deadline (typically 4 months from final denial). External reviewers reverse a meaningful fraction of denials.

Medicare beneficiaries follow a different appeals process — 5 levels of appeal up through the Medicare Appeals Council. The CMS “Medicare Appeals Process” brochure walks through each level.

7. Sample appeal letter (copy-paste template)

[Member name, DOB, Member ID]

[Insurer name, Appeals Address]

Re: Formulary exception appeal — [Drug name]

I am writing to formally appeal the denial dated [date] of [Drug name] for [patient name]. The denial reason cited was [denial reason]. I respectfully request reconsideration based on the following clinical justification:

1. Medical necessity: [Patient name] has documented [diagnosis: e.g. obesity with BMI of X and type 2 diabetes / cardiovascular disease / etc.]. This meets FDA-labeled criteria for [Drug name] per [cite FDA label section].

2. Failure of preferred alternatives: Patient has tried [list alternatives] with [outcome — discontinued for adverse effect, lack of efficacy, contraindication].

3. Clinical guideline support:[Drug name] is recommended for this patient's clinical profile by [AACE Obesity Guideline / ADA Standards of Care / ASMBS position statement — cite specific section].

4. Anticipated outcome without treatment: [Specific clinical risk: e.g. continued A1C above target, progression to insulin requirement, cardiovascular event risk]. Approval of [Drug name] is expected to reduce this risk significantly per [cite trial].

I appreciate your reconsideration. Please contact me at [number] if additional documentation is needed.

Sincerely,
[Prescriber name, credentials, NPI]

8. Manufacturer savings programs

NovoCare (Wegovy, Ozempic, Saxenda, Rybelsus, Victoza)

For commercially-insured patients with coverage: $0-25/month copay (capped annual savings ~$3,600). EXCLUDES Medicare, Medicaid, federally-funded plans. Wegovy uninsured patients without coverage: up to ~$650/month with NovoCare savings.

LillyCares (Zepbound, Mounjaro, Trulicity)

Similar commercial-insurance copay assistance. LillyDirect (separate program) sells Zepbound single-dose vials at fixed cash prices ($349-499/month) regardless of insurance — currently the cheapest path to FDA-approved tirzepatide for patients without weight-management coverage.

Patient Assistance Programs

NovoCare and Lilly each offer means-tested Patient Assistance Programs (PAPs) for patients with documented financial hardship and no insurance coverage of their medication. Application requires proof of income, prescriber verification, and patient attestation.

9. Cash-pay strategies if no coverage

If insurance denies and you proceed with cash-pay, options ranked by cost (cheapest first):

Compounded semaglutide via telehealth: $150-300/month. NOT FDA-approved; verify pharmacy is state-licensed. See deep-dive.
LillyDirect Zepbound vials: $349-499/month. FDA-approved; cash-pay only (no insurance billing).
NovoCare uninsured Wegovy: Up to $650/month with savings card if no coverage available.
Mexico/Canada pharmacy: Personal-import quantities legal in some jurisdictions; significant regulatory grey area. Not recommended without legal counsel.
Cash-pay full list price: $998-1,349/month US pharmacy.

10. HSA / FSA eligibility

GLP-1 medications are eligible expenses for HSA (Health Savings Account) and FSA (Flexible Spending Account) when prescribed for a medical condition (diabetes, obesity with comorbidity, CVD, etc.). The IRS considers these qualified medical expenses under §213(d).

What you need: a prescription (already required to obtain the drug) and a receipt from the pharmacy. Some HSA/FSA administrators may request a Letter of Medical Necessity (LMN) for weight-loss indications — your prescriber can write one citing your BMI + comorbidity.

11. Frequently asked questions

Does Medicare cover Wegovy for weight loss?: Medicare Part D cannot cover Wegovy when prescribed solely for weight loss — this is a statutory exclusion under MMA 2003 §1860D-2(e)(2)(A). However, the FDA approved Wegovy for cardiovascular event reduction in 2024 based on the SELECT trial. Medicare Part D plans began adding coverage for Wegovy under this CVD indication in 2024-2025 for patients with established cardiovascular disease and obesity/overweight.
Why does insurance cover Ozempic but not Wegovy?: Ozempic and Wegovy contain the same active ingredient (semaglutide) but have different FDA-approved uses: Ozempic for type 2 diabetes, Wegovy for chronic weight management. Most insurance plans cover medications based on the FDA-labeled indication. Type 2 diabetes is consistently covered; weight-management coverage varies by plan, employer, and state. Many employers exclude obesity drugs as "lifestyle" medications despite being FDA-approved.
How do I get prior authorization approved for a GLP-1?: Most prior auths require documented BMI ≥30 (or ≥27 with a comorbidity like type 2 diabetes, hypertension, hyperlipidemia, or sleep apnea), a recent A1C if diabetic, documentation of lifestyle intervention attempts, and contraindication screening. Your prescriber submits the form through the insurer's portal; turnaround is typically 24-72 hours. If denied, request the specific denial reason in writing — this informs the appeal strategy.
What can I do if my GLP-1 prescription is denied?: Three-step approach: (1) Request the written denial reason and your plan's formulary exception process. (2) Submit a tier-exception or formulary-exception appeal with prescriber-supplied medical necessity letter citing FDA labels, treatment guidelines, and your failure of other therapies. (3) If denied again, request external review (independent third-party medical review, available under ACA-regulated plans). Many denials are reversed on appeal with proper documentation.
Are there manufacturer savings programs that work with insurance?: Yes, but eligibility is restrictive. NovoCare offers commercially-insured Wegovy and Ozempic patients $0-25/month copay cards (capped annual savings). LillyCares similarly covers Zepbound and Mounjaro for commercially-insured patients. Both programs EXCLUDE Medicare, Medicaid, and uninsured patients due to federal anti-kickback rules. LillyDirect (separate from copay cards) sells Zepbound single-dose vials at $349-499/month cash-pay regardless of insurance.
Does Medicaid cover GLP-1s for weight loss?: Medicaid weight-loss coverage is state-by-state. As of 2026, approximately 13 states explicitly cover GLP-1s for chronic weight management under their Medicaid programs (typically with BMI ≥30 + comorbidity criteria). Most state Medicaids cover diabetes indications consistently. See our state-by-state pages for current coverage status in your state.

Next steps

Coverage policies change frequently. Always verify current coverage with your insurer before assuming. This guide is editorial and does not constitute legal, medical, or insurance advice. Full disclaimer.